Molecular Classification of endometrial cancer and its
Implications

Short Communication - Gynecology and Reproductive Endocrinology (2020) Volume 3, Issue 4

Endometrial cancer (EC) is the most prevalent gynecologic malignancy in the developed world. Majority of women with

EC have good outcomes (80% in stage I, 5 year survival rate ~ 90%)1. Traditional risk group classification into type I

and type II is based on post-surgical staging pathologic examination (principally histotype, tumour grade and stage).

Type I is mostly hormono dependant and has a better prognosis than type II 2. This classification has a lot of limitations

because of the overlap of the two types and the heterogeneity in each one. In addition to that, Interobserver disagreement

in endometrial carcinoma histotype assignment varies from 10% to 20% and reaches 26% to 37% in high-grade tumors 3.

For all these reasons and due to molecular biology advances, ge nomic classification of endometrial carcinoma was issued

by the National Cancer Institute and National Human Genome Research Institute, in 2013 (The cancer genome atlas, TCGA) 4.

Author(s): Nadine El Kassis